NEW YORK--(BUSINESS WIRE)--The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of XBiotech Inc. (“XBiotech”) (Nasdaq: XBIT) between April 15, 2015 and November 23, 2015.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Western District of Texas. If you purchased or otherwise acquired XBiotech securities between April 15, 2015 and November 23, 2015, your rights may be affected by this action. To get more information go to:
or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
According to the complaint, the Company made materially false and misleading statements to investors and/or failed to disclose that: (1) a fewer number of per protocol patients were available for primary endpoint evaluation in the Phase III Study; (2) the data from 72 patients of the Phase III Study was compromised; (3) XBiotech did not adequately sample patients to accommodate data loss; and (4) as a result of not properly sampling patients, the Phase III Study would have reduced statistical power to demonstrate the proposed outcome.
If you suffered a loss in XBiotech you have until February 1, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
